This is a randomized, double-blind, placebo-controlled, parallel-group study evaluating the effects of two distinct Qualia NAD⁺ formulations on intracellular NAD⁺ levels in healthy adults aged 35-75 years. Approximately 180 participants will be randomized to one of three study arms: Qualia NAD⁺ version 1, Qualia NAD⁺ version 2, or placebo. Each participant will take two capsules of their assigned product once daily in the morning, with or without food, over a 28-day period. The primary outcome is the change in intracellular NAD⁺ levels, assessed via at-home finger-stick blood collection at baseline and study completion. Secondary endpoints include changes in aging-related symptoms (AMFS scores), health-related quality of life (RAND SF-36), and evaluation of safety and tolerability. All assessments, including electronic questionnaires, are completed remotely without in-person visits.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
OTHER
Masking
TRIPLE
Enrollment
180
Qualia NAD+ version 1 manufactured by Qualia Life Sciences
Qualia NAD+ version 2 manufactured by Qualia Life Sciences
Rice Flour
Qualia Life Sciences
Carlsbad, California, United States
Between-group change in intracellular NAD⁺ levels
To assess between-group differences in the change in intracellular NAD⁺ levels from baseline to Week 4 following supplementation with Qualia NAD version 1, Qualia NAD version 2, or placebo.
Time frame: 28 days
Aging-Related Symptoms (AMFS scores)
To evaluate within-group and between-group differences in the change in Aging Male/Female Symptom (AMFS) total and sub-scale scores.
Time frame: 4 weeks
RAND SF-36 Scale Scores
To assess within-group and between-group differences in RAND SF-36 domain scores.
Time frame: 4 weeks
Side effect profile as measured by a custom Safety and Tolerability survey
To evaluate side effect profiles using a custom Safety and Tolerability survey.
Time frame: Week 1, 2, 3, and 4
Within-group differences in the change in intracellular NAD⁺ levels
To assess within-group differences in the change in intracellular NAD⁺ levels
Time frame: 4 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.